- Home
- AMAL vs ABCL Comparison
AMAL vs ABCL Comparison
Compare AMAL & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- ABCL
- Stock Information
- Founded
- AMAL 1923
- ABCL 2012
- Country
- AMAL United States
- ABCL Canada
- Employees
- AMAL N/A
- ABCL N/A
- Industry
- AMAL Commercial Banks
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- ABCL Health Care
- Exchange
- AMAL Nasdaq
- ABCL Nasdaq
- Market Cap
- AMAL 867.2M
- ABCL 772.9M
- IPO Year
- AMAL 2018
- ABCL 2020
- Fundamental
- Price
- AMAL $30.22
- ABCL $2.02
- Analyst Decision
- AMAL Buy
- ABCL Strong Buy
- Analyst Count
- AMAL 3
- ABCL 4
- Target Price
- AMAL $36.50
- ABCL $8.33
- AVG Volume (30 Days)
- AMAL 161.7K
- ABCL 4.1M
- Earning Date
- AMAL 07-24-2025
- ABCL 05-08-2025
- Dividend Yield
- AMAL 1.85%
- ABCL N/A
- EPS Growth
- AMAL 9.81
- ABCL N/A
- EPS
- AMAL 3.36
- ABCL N/A
- Revenue
- AMAL $303,970,000.00
- ABCL $23,114,000.00
- Revenue This Year
- AMAL $11.72
- ABCL N/A
- Revenue Next Year
- AMAL $12.48
- ABCL $36.62
- P/E Ratio
- AMAL $8.99
- ABCL N/A
- Revenue Growth
- AMAL 7.13
- ABCL N/A
- 52 Week Low
- AMAL $24.02
- ABCL $1.89
- 52 Week High
- AMAL $38.19
- ABCL $4.20
- Technical
- Relative Strength Index (RSI)
- AMAL 53.57
- ABCL 40.97
- Support Level
- AMAL $29.68
- ABCL $1.97
- Resistance Level
- AMAL $30.90
- ABCL $2.08
- Average True Range (ATR)
- AMAL 0.84
- ABCL 0.10
- MACD
- AMAL -0.11
- ABCL 0.01
- Stochastic Oscillator
- AMAL 40.33
- ABCL 29.63
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.